No benefit seen from adjuvant celecoxib in ERBB2-negative breast cancer

No benefit seen from adjuvant celecoxib in ERBB2-negative breast cancer

(HealthDay)—For patients with ERBB2-negative breast cancer, two years of treatment with celecoxib as adjuvant to conventional therapy yields no disease-free survival (DFS) benefits compared with placebo, according to a study published online July 15 in JAMA Oncology.

R. Charles Coombes, M.D., Ph.D., from Imperial College London, and colleagues conducted a randomized trial in 160 centers testing two years of adjuvant celecoxib versus among 2,639 with ERBB2 (formerly HER2)-negative breast cancer. Participants were randomly assigned to either celecoxib or placebo in a 2:1 ratio (1,763 and 876, respectively).

Overall, 73 percent of the tumors were estrogen receptor-positive or progesterone receptor-positive and ERBB2-negative. Forty-eight percent of patients had node-positive disease and 42 percent had grade 3 tumors. The researchers found that DFS events were reported for 487 patients (19 percent) at a median follow-up of 74.3 months: 18 and 19 percent for those who received celecoxib and placebo, respectively (five-year DFS rates, 84 and 83 percent, respectively), with an unadjusted hazard ratio of 0.97 (95 percent confidence interval, 0.80 to 1.17; log-rank P = 0.75). Across both treatment groups, the rates of toxic effects were low, with no evidence of a difference.

"Despite compelling preclinical and observational evidence suggesting a role for anti-inflammatory agents in the management of breast cancer, celecoxib failed to reduce the risk of recurrence or mortality among individuals with early-stage disease," write the authors of an accompanying editorial.

Several authors disclosed financial ties to biopharmaceutical companies, including Pfizer, which manufactures and partially funded the study.

Explore further

Breast cancer prognosis no better with five versus two years of zoledronate

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Journal information: JAMA Oncology

Copyright © 2021 HealthDay. All rights reserved.

Citation: No benefit seen from adjuvant celecoxib in ERBB2-negative breast cancer (2021, July 16) retrieved 28 September 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors